Prolastin-c Kit
Product Images NDC 13533-706

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Prolastin-c (NDC 13533-706). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Grifols Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Diluent (13533 200 20 Label)

Label for PROLASTIN-C Sterile Water for Injection, USP, 20 mL single-dose container. The label states it is for reconstitution of the accompanying product and includes usage instructions and manufacturer information: Laboratorios Grifols, S.A. in Spain and Grifols Therapeutics LLC in North Carolina, USA. Marked Rx Only.*

FDA Label Image

Prolastin Vial (13533 702 11 Label)

Label for PROLASTIN-C, Alpha-1-Proteinase Inhibitor (Human) plasma derivative kit by Grifols USA, LLC. The label indicates the product is solvent detergent treated and nanofiltered. It includes storage instructions, usage notes, and manufacturer details, with NDC 13533-702-11 visible.*

FDA Label Image

Carton (13533 703 10 Carton)

Packaging label for PROLASTIN-C, Alpha-1-Proteinase Inhibitor (Human) plasma derivative kit by Grifols. The label states the product is solvent detergent treated and nanofiltered. The carton includes warnings about human plasma origin and instructions for reconstitution with 20 mL sterile water. Contents listed include one vial of PROLASTIN-C, diluent, sterile needles, and specifies intravenous administration only. Storage instructions indicate to keep below 25°C and avoid freezing.*

FDA Label Image

76297 002 22

Label for Sterile Water for Injection, USP in a 20 mL single-dose container, marked Rx Only. The product is for reconstitution of an accompanying product and is nonpyrogenic. It specifies usage instructions including discard of unused portions. Manufactured by Laboratorios Grifols, S.A., Barcelona, Spain.*

FDA Label Image

Prolastin-c Figure 1 (Prolastinc Figure 1)

A line graph showing mean plasma Alpha-1-Proteinase Inhibitor concentration (mg/mL) over nominal time (hours) comparing PROLASTIN-C and PROLASTIN. The graph depicts a decline in concentration from near 1.8 mg/mL at time zero to about 0.5 mg/mL at 240 hours for both products with closely overlapping curves.*

FDA Label Image

Prolastin-c Reconstitution Method (Prolastincfigureaandb)

Illustration showing two steps of medication preparation from the PROLASTIN-C kit. Figure A depicts a gloved hand inserting a syringe into a vial, while Figure B shows a gloved hand rotating the vial in a circular motion. This instructional image demonstrates vial handling as part of the preparation process for the plasma derivative product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.